Global biopharma financing closed out 2025 on its strongest footing in years: Q4 was among the strongest quarters for financing in over four years, with more than $30 billion raised by biopharma companies worldwide, according to SwedenBIO’s Life Science Barometer 2026.
Large pharma spent more than $200 billion on M&A over the year to refill its pipeline, the most since 2019, pushing the NASDAQ Biotechnology Index to new all-time highs.
The Global Rebound
The recovery follows several lean years after the pandemic-era peak. Total M&A value climbed to $205 billion across 155 acquisitions in 2025, up from $82 billion in 2024, though deal volume has trended down from a peak of 220 acquisitions in 2020. Fewer, larger deals are increasingly the pattern: pharma is concentrating capital on higher-conviction bets rather than spreading it across a wider set of smaller acquisitions.
The Competitive Landscape
Capital availability is not spreading evenly across the global biotech map. Recent years have seen remarkable growth within biotech companies in China and South Korea, while Europe has held comparatively steady. As competition for capital grows more global, the bar for capturing investor attention keeps rising, meaning European and other non-US, non-China ecosystems increasingly compete for a share of the same pool of international investors.
Policy Tailwinds
New public funding schemes are emerging to help close that gap. The proposed €10 billion BioTechEU initiative is intended to provide further support for European biotechs seeking capital, though access to major investors in the US and broader Europe will continue to depend on strong underlying science and a compelling commercial pathway.
About the data
The Swedish funding count is sourced from public disclosures and may not capture undisclosed or smaller private rounds. Global financing and M&A figures reflect data available at time of publication and are subject to revision as more deals are disclosed.
Source: SwedenBIO, Life Science Barometer 2026, with international outlook data from Citeline’s Biomedtracker and Pharmaprojects databases (Norstella).
